Skip to content

Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy

Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy: a Randomized Controlled Clinical Study

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07497958
Enrollment
174
Registered
2026-03-27
Start date
2026-04-01
Completion date
2028-12-31
Last updated
2026-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cell Carcinoma (RCC), Renal Function Abnormal

Keywords

Renal Function Abnormal, Acute kidney injury, Partial nephrectomy, Ischemic preconditioning

Brief summary

It is demonstrated that remote ischemic preconditioning can alleviate the degree of acute renal injury on the operated side in patients undergoing partial nephrectomy.

Detailed description

The study cohort was randomly divided into two groups. One group received remote ischemic preconditioning one day before partial nephrectomy, while the other group underwent partial nephrectomy directly. The degree of acute renal injury on the operated side was compared between the two groups

Interventions

PROCEDUREIschemic preconditioning

One day before the surgery, use a sphygmomanometer to apply pressure to the patient's upper limb to 200mmHg for 5 minutes, then reduce the pressure to 0mmHg for 5 minutes, repeating this process for a total of 3 cycles. On the second day, perform a routine partial nephrectomy

Routine partial nephrectomy

Sponsors

Sun Yat-sen University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

The study cohort was randomly divided into two groups. One group received remote ischemic preconditioning one day before partial nephrectomy, while the other group underwent partial nephrectomy directly. The degree of acute renal injury on the operated side was compared between the two groups

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients who are scheduled to undergo partial nephrectomy, with no specific surgical procedure limitation, including laparoscopic surgery, robot-assisted surgery, and open surgery * Aged 18 to 80 * Possess good organ function status: sufficient organ function (based on the normal values of the clinical trial center) 1. Blood routine test: WBC≥3.5×10\^9/L, absolute neutrophil count ≥1.5×10\^9/L, PLT≥75.0×10\^9/L, HGB≥80g/L; 2. Liver function: Total bilirubin ≤1.5×upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN;

Exclusion criteria

* The anesthesiologist assesses that the patient cannot tolerate general anesthesia surgery * Individuals with severe cardiovascular and cerebrovascular diseases, uncontrolled hypertension, and diabetes * Estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73m² * Horseshoe kidney * Solitary kidney * Pregnant women

Design outcomes

Primary

MeasureTime frameDescription
AIRD spectrum score based on the patient's preoperative creatinine level and postoperative peak creatinine level2 weeks after partial nephrectomyThe AIRD spectrum score was defined as: (observed peak SCr - SCr ideal-peak)/(SCr worstcase-peak - SCr ideal-peak) The range of this indicator should be between 0 and 1, with 0 and 1 representing two extreme situations. 0 indicates that the kidney on the operated side is completely undamaged, while 1 indicates that the kidney on the operated side has completely lost its function.

Secondary

MeasureTime frameDescription
Recovery from ischemia based on the changes in creatinine levels before and after the partial nephrectomy and volume retention rate after the partial nephrectomy3 month after surgeryRecovery from ischemia = (%GFR saved)/(%parenchymal mass preserved)

Countries

China

Contacts

CONTACTFangjian Zhou, professor
zhoufj@sysucc.org.cn020-87343865
PRINCIPAL_INVESTIGATORFangjian Zhou, professor

Sun Yat-sen University Cancer Center (SYSUCC)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026